ROKIT
Develops hybrid modular 3D bioprinters (INVIVO series) and AI-powered organ regeneration platforms for chronic disease treatment, enabling multi-material extrusion with filament, syringe, and hot melt systems.
- CEO / Founder
- Seok-hwan You
- Team Size
- 51-200
- Stage
- Active
- Total Funding
- $93.4M
- Latest Round
- Undisclosed
- Key Investors
- Korea Development Bank; KB Investment; Widwin Investment; Weiss Asset Management LP; LMR Partners LLC; Oasis Management; PAG
Technology & Products
Key Products
INVIVO 3D bioprinter; Dr. INVIVO software; INVIVO-GEL bioinks; Organ Regeneration Platform; 3DISON PRO AEP desktop 3D printer
Technological Advantage
Proprietary 4D bioprinting technology achieves contamination-free organ regeneration with 95% cell viability, protected by domestic and international patents (e.g., for 3DISON PRO AEP).
Differentiation
Value Proposition
Reduces diabetic foot ulcer treatment costs by 60% through automated 3D bioprinting of autologous skin grafts, cutting healing time from 12 weeks to 4 weeks with FDA/CE-MDR approved technology.
How They Differentiate
3x faster print speed than CELLINK BIO X (15 cm³/hr vs 5 cm³/hr) with hybrid modular system allowing multi-material extrusion in one device; 40% lower cost-per-part for skin grafts vs Allevi's solutions.
Market & Competition
Target Customers
Hospitals, research institutions, regenerative medicine clinics, and pharmaceutical companies
Industry Verticals
Medical; Biotechnology; Healthcare
Competitors
CELLINK; Allevi; Regemat 3D
Growth & Milestones
Growth Metrics
Enterprise value tripled after 2019 funding round of 11 billion KRW (~$8.4M); revenue growth driven by FDA/CE approvals for medical bioprinting.
Major Milestones
FDA approval for organ regeneration platform (2023); CE-MDR certification (2023); Excellent Company Award from Ministry of Science and ICT (2022); Launch of INVIVO 3D bioprinter (2020)
Notable Customers
Seoul National University Hospital; Korea Institute of Science and Technology (KIST); Catholic University of Korea; University of Ulsan College of Medicine; Asan Medical Center